Questions on price of LentiGlobinThe potentially huge price of bluebird bio's gene therapy for transfusion-dependent beta thalassemia LentiGlobin raises concerns about its sustainability for German payers, Handelsblatt wrote on Thursday (p9) (APMHE 61565).
German parallel import quota savedThe German parallel import quota for drugs that the Health Minister Jens Spahn was considering abolishing has been saved thanks to pressure from politicians supporting Germany's biggest drug importer, Kohlpharma, Frankfurter Allgemeine Zeitung (FAZ) writes on Friday (p19) (APMHE 61581).
German Health Minister eyes cost-containment on gene therapiesGerman Health Minister Jens Spahn is looking for cost-saving opportunities on gene therapies, he said in an interview with FAZ on Tuesday (APMHE 61525).
Merck KGaA signs deal with Chinese tech giant TencentMerck KGaA wants to develop digital health services in China with internet company Tencent, reported FAZ on Thursday (p41) (APMHE 61542).
BioNTech buys partner's antibody production unitGerman biotech BioNTech has announced the acquisition of the antibody production unit of Mab Discovery, a Munich-based biotech company, reported FAZ on Thursday (p18).
Culture shock at BoehringerBoehringer Ingelheim's former chief finance officer Simone Menne experienced the 'culture shock' that German managers can face when they move from a corporation to a medium-sized company, Manager Magazin writes on Friday (p74-78).
Pharmacists' association asks for ban on online pharmacy discountsGerman pharmacists' association ABDA has called on Health Minister Jens Spahn to prohibit discounts that online pharmacies offer to customers ordering prescription drugs, reported FAZ on Saturday (p8) and Sueddeutsche Zeitung (SZ) on Monday (p17).
Long-term investments in biotech needed to see returnsBiotech investments need to be long-term in order for shareholders to get positive returns, writes weekly Wirtschaftswoche on Friday (p76-78) in a review of several companies.
Contraceptive SPCs to warn about depressionThe leaflets of hormonal contraceptives will be updated to warn about mental side effects such as depression and suicidal thoughts, Die Welt reported on Tuesday (p20).
Bias in results of trials sponsored by pharma companiesTrials sponsored by pharma companies are creating biased results as they are "prone to systemic errors", SZ reported on Tuesday (p13).
TRY APM HEALTH EUROPE AND GET ACCESS TO THE FULL CONTENT
Interviews with KOLs/senior executives amongst the Regulators, Payers, Health, Medical & Pharmaceutical organisations
Events coverage with a unique focus on Market Access & sustainability of healthcare systems
6 European bureaus : Berlin, Brussels, London, Madrid, Milan & Paris
Ask for a Free trial and get access to the latest stories
- Health Care
- Market Access
- HTA – policies & practices
- European medicine regulations
- Drug safety issues
- Pricing & Reimbursement
- International medicines agencies
If you are a Payer, Pharmaceutical or Consulting professional our premium data will keep you informed on the regulatory, pricing, market access and cost-effectiveness issues that impact all stakeholders.
an initial 10 day temporary access of APM Health Europe.